CD274 and neoplasm: This phase II multicohort study included all comers with ≥ 1 prior systemic treatment for metastatic disease regardless of PD-L1 status (Cohort A)[15], and also patients with no prior systemic treatment in the metastatic setting who had PD-L1 positive tumours defined as combined positive score (CPS) ≥ 1 based on the Dako PD-L1 IHC 22C3 platform (Cohort B)[16].